A Population Pharmacokinetic Model of (R)‐ and (S‐) Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers
Open Access
- 28 December 2020
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 61 (7) , 961-971
Abstract
Oxybutynin is a racemic anticholinergic drug used for the symptomatic treatment of detrusor overactivity. The formation of active metabolites related to tolerability problems depends on the route of administration. The objective of this evaluation was to develop a pharmacokinetic model for oral/intravesical administration as the basis for simulations with different dosages. Data from a published changeover clinical study with 18 healthy adults receiving a single oral dose of 5 mg immediate‐release oxybutynin and single and multiple intravesical doses of 10 mg oxybutynin solution was evaluated. Enantioselective plasma concentrations of oxybutynin and N‐desethyloxybutynin (NDO) were used to establish a population pharmacokinetic model using nonlinear mixed‐effects modeling with NONMEM 7.4.1. For both enantiomers, the data were described well by a 2‐compartment model for oxybutynin with an additional compartment for NDO. Oxybutynin absorption was modeled by transit compartments for oral and first‐order absorption for intravesical application. Bioavailability of the more active (R)‐enantiomer was 7% for oral and 10%‐22% for intravesical administration. In simulations, intravesical doses of 5 to 15 mg (R)‐oxybutynin administered 2 to 3 times daily decreased peak‐trough fluctuations of NDO to 8% compared with 24% after oral administration. The NDO/oxybutynin ratio was reduced from 17 after oral administration to unity. Chronic intravesical versus oral administration of (R)‐oxybutynin generates distinctly lower and less variable concentrations of (R)‐NDO. Pharmacokinetic simulations suggest that exposure for 12.5 mg (R)‐oxybutynin administered twice daily might not compromise efficacy and tolerability compared with exposure for standard thrice‐daily administrations. This assumption needs to be assessed in clinical studies.Keywords
This publication has 42 references indexed in Scilit:
- Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and XposeCPT: Pharmacometrics & Systems Pharmacology, 2013
- Handling Data Below the Limit of Quantification in Mixed Effect ModelsThe AAPS Journal, 2009
- Stereoselective pharmacokinetics of oxybutynin andN-desethyloxybutyninin vitroandin vivoXenobiotica, 2007
- THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”Drug Metabolism and Disposition, 2006
- Effect of OROS® controlled‐release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chlorideBritish Journal of Clinical Pharmacology, 2001
- A SHORT-TERM, MULTICENTER, RANDOMIZED DOUBLE-BLIND DOSE TITRATION STUDY OF THE EFFICACY AND ANTICHOLINERGIC SIDE EFFECTS OF TRANSDERMAL COMPARED TO IMMEDIATE RELEASE ORAL OXYBUTYNIN TREATMENT OF PATIENTS WITH URGE URINARY INCONTINENCEJournal of Urology, 2001
- A Size Standard for PharmacokineticsClinical Pharmacokinetics, 1996
- The importance of modeling interoccasion variability in population pharmacokinetic analysesJournal of Pharmacokinetics and Biopharmaceutics, 1993
- Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteersXenobiotica, 1992
- Studies on metabolic fate of oxybutynin hydrochloride. (3). Metabolism in human and dog and the site of biotransfornation and the effect on enzymes induction in the rats.Drug Metabolism and Pharmacokinetics, 1986